[HTML][HTML] Integrative clinical genomics of advanced prostate cancer
Toward development of a precision medicine framework for metastatic, castration-resistant
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …
prostate cancer (mCRPC), we established a multi-institutional clinical sequencing …
Combination of TMB and CNA stratifies prognostic and predictive responses to immunotherapy across metastatic cancer
L Liu, X Bai, J Wang, XR Tang, DH Wu, SS Du… - Clinical Cancer …, 2019 - AACR
Purpose: Although tumor mutation burden (TMB) has been well known to predict the
response to immune checkpoint inhibitors (ICI), lack of randomized clinical trial data has …
response to immune checkpoint inhibitors (ICI), lack of randomized clinical trial data has …
Genomic hallmarks of localized, non-indolent prostate cancer
Prostate tumours are highly variable in their response to therapies, but clinically available
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …
prognostic factors can explain only a fraction of this heterogeneity. Here we analysed 200 …
Suppressing fatty acid uptake has therapeutic effects in preclinical models of prostate cancer
Metabolism alterations are hallmarks of cancer, but the involvement of lipid metabolism in
disease progression is unclear. We investigated the role of lipid metabolism in prostate …
disease progression is unclear. We investigated the role of lipid metabolism in prostate …
[HTML][HTML] Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death
The level of copy number alteration (CNA), termed CNA burden, in the tumor genome is
associated with recurrence of primary prostate cancer. Whether CNA burden is associated …
associated with recurrence of primary prostate cancer. Whether CNA burden is associated …
Molecular biomarkers in localized prostate cancer: ASCO guideline
PURPOSE This guideline provides recommendations for available tissue-based prostate
cancer biomarkers geared toward patient selection for active surveillance, identification of …
cancer biomarkers geared toward patient selection for active surveillance, identification of …
[HTML][HTML] Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer
During disease progression from primary towards metastatic prostate cancer (PCa), and in
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …
particular bone metastases, the tumor microenvironment (TME) evolves in parallel with the …
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer
Tumor heterogeneity may reduce the efficacy of molecularly guided systemic therapy for
cancers that have metastasized. To determine whether the genomic alterations in a single …
cancers that have metastasized. To determine whether the genomic alterations in a single …
[HTML][HTML] Overview on clinical relevance of intra-tumor heterogeneity
G Stanta, S Bonin - Frontiers in medicine, 2018 - frontiersin.org
Today, clinical evaluation of tumor heterogeneity is an emergent issue to improve clinical
oncology. In particular, intra-tumor heterogeneity (ITH) is closely related to cancer …
oncology. In particular, intra-tumor heterogeneity (ITH) is closely related to cancer …
Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer
AA Hamid, KP Gray, G Shaw, LE MacConaill, C Evan… - European urology, 2019 - Elsevier
Abstract Background TP53, PTEN, and RB1 tumor suppressor genes (TSGs) are recurrently
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …
altered in treatment-resistant prostate cancer. Cooperative loss of two or more TSGs may …